Exscientia (NASDAQ:EXAI) Shares Down 5.3% – Time to Sell?

Exscientia plc (NASDAQ:EXAI)’s share price dropped 5.3% on Friday . The stock traded as low as $5.01 and last traded at $5.03. Approximately 147,384 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 640,736 shares. The stock had previously closed at $5.31.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on EXAI. Barclays restated an “equal weight” rating and set a $5.00 price objective on shares of Exscientia in a report on Tuesday, August 13th. TD Cowen reaffirmed a “hold” rating on shares of Exscientia in a report on Friday, August 9th.

Exscientia Stock Down 11.7 %

The stock has a 50-day moving average of $5.04 and a 200-day moving average of $5.15. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.54 and a quick ratio of 5.93. The firm has a market cap of $595.71 million, a price-to-earnings ratio of -3.11 and a beta of 0.83.

Exscientia (NASDAQ:EXAI) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.05). Exscientia had a negative return on equity of 49.10% and a negative net margin of 882.09%. The firm had revenue of $5.60 million for the quarter. Sell-side analysts predict that Exscientia plc will post -1.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its holdings in shares of Exscientia by 66.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,576 shares of the company’s stock valued at $47,000 after purchasing an additional 3,821 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Exscientia during the second quarter worth $54,000. International Assets Investment Management LLC bought a new position in shares of Exscientia in the 3rd quarter valued at $77,000. XTX Topco Ltd acquired a new stake in shares of Exscientia during the 3rd quarter valued at $82,000. Finally, Federated Hermes Inc. bought a new stake in Exscientia during the 2nd quarter worth $115,000. Institutional investors and hedge funds own 41.58% of the company’s stock.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.